Cargando…

Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma

SIMPLE SUMMARY: The primary treatment of malignant melanoma is a classical regimen of surgery combined with chemotherapy, targeted drugs, and immunotherapy. The purpose of this study was to explore the immune response mechanism of RNA binding protein RBM38 in the development of melanoma with the scr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jinfang, Xu, Jun, Luo, Binlin, Tang, Jian, Hou, Zuoqiong, Zhu, Zhechen, Zhu, Lingjun, Yao, Gang, Li, Chujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946480/
https://www.ncbi.nlm.nih.gov/pubmed/35326741
http://dx.doi.org/10.3390/cancers14061590
_version_ 1784674203297906688
author Liu, Jinfang
Xu, Jun
Luo, Binlin
Tang, Jian
Hou, Zuoqiong
Zhu, Zhechen
Zhu, Lingjun
Yao, Gang
Li, Chujun
author_facet Liu, Jinfang
Xu, Jun
Luo, Binlin
Tang, Jian
Hou, Zuoqiong
Zhu, Zhechen
Zhu, Lingjun
Yao, Gang
Li, Chujun
author_sort Liu, Jinfang
collection PubMed
description SIMPLE SUMMARY: The primary treatment of malignant melanoma is a classical regimen of surgery combined with chemotherapy, targeted drugs, and immunotherapy. The purpose of this study was to explore the immune response mechanism of RNA binding protein RBM38 in the development of melanoma with the screening of effective immunodiagnostic models and targeted therapy. We found that RBM38, as an oncogene, promotes the proliferation, invasion, and migration of melanoma cells and is associated with immune infiltration and pathways. Our investigation presented the prognostic significance of RBM38-associated immune signature. In addition, this model may provide a potential strategy for improving the survival and immunotherapy of melanoma patients. ABSTRACT: Background: Current studies have revealed that RNA-binding protein RBM38 is closely related to tumor development, while its role in malignant melanoma remains unclear. Therefore, this research aimed to investigate the function of RBM38 in melanoma and the prognosis of the disease. Methods: Functional experiments (CCK-8 assay, cell colony formation, transwell cell migration/invasion experiment, wound healing assay, nude mouse tumor formation, and immunohistochemical analysis) were applied to evaluate the role of RBM38 in malignant melanoma. Immune-associated differentially expressed genes (DEGs) on RBM38 related immune pathways were comprehensively analyzed based on RNA sequencing results. Results: We found that high expression of RBM38 promoted melanoma cell proliferation, invasion, and migration, and RBM38 was associated with immune infiltration. Then, a five-gene (A2M, NAMPT, LIF, EBI3, and ERAP1) model of RBM38-associated immune DEGs was constructed and validated. Our signature showed superior prognosis capacity compared with other melanoma prognostic signatures. Moreover, the risk score of our signature was connected with the infiltration of immune cells, immune-regulatory proteins, and immunophenoscore in melanoma. Conclusions: We constructed an immune prognosis model using RBM38-related immune DEGs that may help evaluate melanoma patient prognosis and immunotherapy modalities.
format Online
Article
Text
id pubmed-8946480
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89464802022-03-25 Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma Liu, Jinfang Xu, Jun Luo, Binlin Tang, Jian Hou, Zuoqiong Zhu, Zhechen Zhu, Lingjun Yao, Gang Li, Chujun Cancers (Basel) Article SIMPLE SUMMARY: The primary treatment of malignant melanoma is a classical regimen of surgery combined with chemotherapy, targeted drugs, and immunotherapy. The purpose of this study was to explore the immune response mechanism of RNA binding protein RBM38 in the development of melanoma with the screening of effective immunodiagnostic models and targeted therapy. We found that RBM38, as an oncogene, promotes the proliferation, invasion, and migration of melanoma cells and is associated with immune infiltration and pathways. Our investigation presented the prognostic significance of RBM38-associated immune signature. In addition, this model may provide a potential strategy for improving the survival and immunotherapy of melanoma patients. ABSTRACT: Background: Current studies have revealed that RNA-binding protein RBM38 is closely related to tumor development, while its role in malignant melanoma remains unclear. Therefore, this research aimed to investigate the function of RBM38 in melanoma and the prognosis of the disease. Methods: Functional experiments (CCK-8 assay, cell colony formation, transwell cell migration/invasion experiment, wound healing assay, nude mouse tumor formation, and immunohistochemical analysis) were applied to evaluate the role of RBM38 in malignant melanoma. Immune-associated differentially expressed genes (DEGs) on RBM38 related immune pathways were comprehensively analyzed based on RNA sequencing results. Results: We found that high expression of RBM38 promoted melanoma cell proliferation, invasion, and migration, and RBM38 was associated with immune infiltration. Then, a five-gene (A2M, NAMPT, LIF, EBI3, and ERAP1) model of RBM38-associated immune DEGs was constructed and validated. Our signature showed superior prognosis capacity compared with other melanoma prognostic signatures. Moreover, the risk score of our signature was connected with the infiltration of immune cells, immune-regulatory proteins, and immunophenoscore in melanoma. Conclusions: We constructed an immune prognosis model using RBM38-related immune DEGs that may help evaluate melanoma patient prognosis and immunotherapy modalities. MDPI 2022-03-21 /pmc/articles/PMC8946480/ /pubmed/35326741 http://dx.doi.org/10.3390/cancers14061590 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Jinfang
Xu, Jun
Luo, Binlin
Tang, Jian
Hou, Zuoqiong
Zhu, Zhechen
Zhu, Lingjun
Yao, Gang
Li, Chujun
Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma
title Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma
title_full Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma
title_fullStr Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma
title_full_unstemmed Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma
title_short Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma
title_sort immune landscape and an rbm38-associated immune prognostic model with laboratory verification in malignant melanoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946480/
https://www.ncbi.nlm.nih.gov/pubmed/35326741
http://dx.doi.org/10.3390/cancers14061590
work_keys_str_mv AT liujinfang immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT xujun immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT luobinlin immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT tangjian immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT houzuoqiong immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT zhuzhechen immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT zhulingjun immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT yaogang immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma
AT lichujun immunelandscapeandanrbm38associatedimmuneprognosticmodelwithlaboratoryverificationinmalignantmelanoma